Aytu BioPharma Inc’s filing revealed that its Chief Executive Officer Disbrow Joshua R. acquired Company’s shares for reported $19500.0 on Feb 28 ’25. In the deal valued at $1.30 per share,15,000 shares were bought. As a result of this transaction, Disbrow Joshua R. now holds 86,591 shares worth roughly $0.18 million.
Cantor Fitzgerald initiated its Aytu BioPharma Inc [AYTU] rating to an Overweight in a research note published on March 30, 2021; the price target was $11. A number of analysts have revised their coverage, including H.C. Wainwright’s analysts, who began to cover the stock in late May with a ‘”a Buy”‘ rating.
Price Performance Review of AYTU
On Friday, Aytu BioPharma Inc [NASDAQ:AYTU] saw its stock fall -17.76% to $2.13. Over the last five days, the stock has gained 70.40%. Aytu BioPharma Inc shares have risen nearly 25.29% since the year began. Nevertheless, the stocks have fallen -35.84% over the past one year. While a 52-week high of $3.35 was reached on 05/15/25, a 52-week low of $0.95 was recorded on 04/07/25. SMA at 50 days reached $1.22, while 200 days put it at $1.76.
Levels Of Support And Resistance For AYTU Stock
The 24-hour chart illustrates a support level at 1.97, which if violated will result in even more drops to 1.82. On the upside, there is a resistance level at 2.37. A further resistance level may holdings at 2.62. The Relative Strength Index (RSI) on the 14-day chart is 69.99, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.60, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 34.76%. Stochastics %K at 76.66% indicates the stock is a holding.
